Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
ZUG, Switzerland, Feb. 5, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will webcast a live fireside chat, featuring Thomas Meyer, Chairman and CEO, at the 2016 Leerink Global Healthcare Conference on Thursday, February 11, 2015, at 8:30 a.m. EST from the Waldorf Astoria Hotel in New York. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Auris Medical Leerink Conference Presentation http://hugin.info/160190/R/1984071/727288.pdf
HUG#1984071
CONTACTS: Auris Medical contacts:
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94,
[email protected]
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685,
[email protected]
